{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:09:16Z","timestamp":1790352556172,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100017531","name":"Medical and Health Research Project of Zhejiang Province","doi-asserted-by":"crossref","award":["2020KY079"],"award-info":[{"award-number":["2020KY079"]}],"id":[{"id":"10.13039\/501100017531","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"crossref","award":["Y-2019AZMS-0061"],"award-info":[{"award-number":["Y-2019AZMS-0061"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Beijing Science and Technology Innovation Medical Development Foundation","award":["KC2021-JX-0186-63"],"award-info":[{"award-number":["KC2021-JX-0186-63"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-73177-2","type":"journal-article","created":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T11:30:01Z","timestamp":1733225401000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Long-term survival and failure patterns in inoperable early-stage non-small cell lung cancer following stereotactic body radiotherapy: a single-institution retrospective study"],"prefix":"10.1038","volume":"14","author":[{"given":"Lin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuojun","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baiqiang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglian","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,3]]},"reference":[{"issue":"3","key":"73177_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71 (3), 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"73177_CR2","doi-asserted-by":"crossref","unstructured":"Tandberg, D. J. et al. Surgery versus stereotactic body radiation therapy for stage I non-small cell lung cancer: a comprehensive review. Cancer 124(4), 667\u2013678 (2018) .","DOI":"10.1002\/cncr.31196"},{"key":"73177_CR3","doi-asserted-by":"crossref","unstructured":"Akamine, T. et al. Feasibility and effectiveness of segmentectomy versus wedge resection for clinical stage I non-small-cell lung cancer. Eur. J. Cardiothorac. Surg. 63(3), (2023).","DOI":"10.1093\/ejcts\/ezad018"},{"key":"73177_CR4","doi-asserted-by":"crossref","unstructured":"Shinde, A. et al. Stereotactic body radiation therapy (SBRT) for early-stage lung cancer in the elderly. Semin. Oncol. 45(4), 210\u2013219 (2018) .","DOI":"10.1053\/j.seminoncol.2018.06.002"},{"key":"73177_CR5","doi-asserted-by":"crossref","unstructured":"Milic, M., Mondini, M. & Deutsch, E. How to improve SBRT outcomes in NSCLC: from pre-clinical modeling to successful clinical Translation. Cancers (Basel) 14(7), (2022).","DOI":"10.3390\/cancers14071705"},{"issue":"1","key":"73177_CR6","first-page":"26","volume":"25","author":"X Liu","year":"2022","unstructured":"Liu, X., Li, X. & Yang, F. Pattern of recurrence and metastasis after Radical Resection of Non-small Cell Lung Cancer. Zhongguo Fei Ai Za Zhi 25 (1), 26\u201333 (2022).","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"73177_CR7","doi-asserted-by":"crossref","unstructured":"Spagnuolo, A. & Gridelli, C. Combining immunotherapies to treat non-small cell lung cancer. Expert Rev. Respir Med. 13(7), 621\u2013634 (2019) .","DOI":"10.1080\/17476348.2019.1623027"},{"key":"73177_CR8","doi-asserted-by":"crossref","unstructured":"Rizwi, F. A. et al. Janus kinase-Signal transducer and activator of transcription inhibitors for the treatment and management of Cancer. J. Environ. Pathol. Toxicol. Oncol. 42(4), 15\u201329 (2023) .","DOI":"10.1615\/JEnvironPatholToxicolOncol.2023045403"},{"key":"73177_CR9","first-page":"1","volume":"42","author":"M Provencio","year":"2022","unstructured":"Provencio, M. et al. Treatment sequencing in resectable lung cancer: the good and the bad of adjuvant versus neoadjuvant therapy. Am. Soc. Clin. Oncol. Educ. Book. 42, 1\u201318 (2022).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"issue":"21","key":"73177_CR10","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde, P. M. et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N. Engl. J. Med. 386 (21), 1973\u20131985 (2022).","journal-title":"N Engl. J. Med."},{"issue":"3","key":"73177_CR11","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/s41591-020-01224-2","volume":"27","author":"T Cascone","year":"2021","unstructured":"Cascone, T. et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat. Med. 27 (3), 504\u2013514 (2021).","journal-title":"Nat. Med."},{"key":"73177_CR12","doi-asserted-by":"crossref","unstructured":"Bernstein, M. B. et al. Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? Nat. Rev. Clin. Oncol. 13(8), 516\u2013524 (2016).","DOI":"10.1038\/nrclinonc.2016.30"},{"key":"73177_CR13","doi-asserted-by":"crossref","unstructured":"Ramli, S. et al. Long noncoding RNA UCA1 in gastrointestinal cancers: Molecular regulatory roles and patterns, mechanisms, and interactions. J. Oncol. 2021, 5519720 (2021).","DOI":"10.1155\/2021\/5519720"},{"key":"73177_CR14","doi-asserted-by":"crossref","unstructured":"Chang, J. Y. et al. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet 402(10405), 871\u2013881 (2023).","DOI":"10.1016\/S0140-6736(23)01384-3"},{"key":"73177_CR15","doi-asserted-by":"crossref","unstructured":"Timmerman, R. et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 303(11), 1070\u20131076 (2010) .","DOI":"10.1001\/jama.2010.261"},{"key":"73177_CR16","doi-asserted-by":"crossref","unstructured":"Giuliani, M. et al. SUNSET: Stereotactic radiation for ultracentral non-small-cell lung cancer\u2014a safety and efficacy trial. Clin. Lung Cancer 19(4), e529\u2013e532 (2018) .","DOI":"10.1016\/j.cllc.2018.04.001"},{"key":"73177_CR17","doi-asserted-by":"crossref","unstructured":"Shi, Y. et al. Comparison between wedge resection and lobectomy\/segmentectomy for early-stage non-small cell lung cancer: a bayesian Meta-analysis and systematic review. Ann. Surg. Oncol. 29(3), 1868\u20131879 (2022).","DOI":"10.1245\/s10434-021-10857-7"},{"key":"73177_CR18","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.lungcan.2016.11.002","volume":"102","author":"ML Wong","year":"2016","unstructured":"Wong, M. L. et al. Impact of age and comorbidity on treatment of non-small cell lung cancer recurrence following complete resection: a nationally representative cohort study. Lung Cancer 102, 108\u2013117 (2016).","journal-title":"Lung Cancer"},{"issue":"9","key":"73177_CR19","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1001\/jamaoncol.2018.1251","volume":"4","author":"RD Timmerman","year":"2018","unstructured":"Timmerman, R. D. et al. Stereotactic body radiation therapy for operable early-stage lung cancer: findings from the NRG Oncology RTOG 0618 Trial. JAMA Oncol. 4 (9), 1263\u20131266 (2018).","journal-title":"JAMA Oncol."},{"issue":"9","key":"73177_CR20","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1001\/jamaoncol.2018.1258","volume":"4","author":"RD Timmerman","year":"2018","unstructured":"Timmerman, R. D. et al. Long-term results of stereotactic body radiation therapy in medically inoperable stage I non-small cell lung Cancer. JAMA Oncol. 4 (9), 1287\u20131288 (2018).","journal-title":"JAMA Oncol."},{"key":"73177_CR21","doi-asserted-by":"crossref","unstructured":"Onishi, H. et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer 101(7), 1623\u20131631  (2004).","DOI":"10.1002\/cncr.20539"},{"key":"73177_CR22","doi-asserted-by":"crossref","unstructured":"Kang, J. et al. Predicting 5-year progression and survival outcomes for early stage non-small cell lung cancer treated with stereotactic ablative radiation therapy: Development and validation of robust prognostic nomograms. Int. J. Radiat. Oncol. Biol. Phys. 106(1), 90\u201399 (2020).","DOI":"10.1016\/j.ijrobp.2019.09.037"},{"key":"73177_CR23","doi-asserted-by":"crossref","unstructured":"Tonneau, M. et al. A competing risk analysis of the patterns and risk factors of recurrence in early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy. Radiother. Oncol.185, 109697 (2023).","DOI":"10.1016\/j.radonc.2023.109697"},{"issue":"4","key":"73177_CR24","doi-asserted-by":"publisher","first-page":"340","DOI":"10.6004\/jnccn.2023.0020","volume":"21","author":"DS Ettinger","year":"2023","unstructured":"Ettinger, D. S. et al. NCCN guidelines(R) insights: Non-small cell lung cancer, Version 2. J. Natl. Compr. Cancer Netw. 21 (4), 340\u2013350 (2023).","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"73177_CR25","doi-asserted-by":"crossref","unstructured":"Postmus, P. E. et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. A28nn. Oncol.  28(suppl_4), iv1\u2013iv21 (2017).","DOI":"10.1093\/annonc\/mdx222"},{"issue":"2","key":"73177_CR26","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.jtcvs.2017.02.065","volume":"154","author":"BA Yerokun","year":"2017","unstructured":"Yerokun, B. A. et al. A national analysis of wedge resection versus stereotactic body radiation therapy for stage IA non-small cell lung cancer. J. Thorac. Cardiovasc. Surg. 154 (2), 675\u2013686 (2017).","journal-title":"J. Thorac. Cardiovasc. Surg."},{"issue":"2","key":"73177_CR27","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.radonc.2014.08.031","volume":"112","author":"B Zhang","year":"2014","unstructured":"Zhang, B. et al. Matched-pair comparisons of stereotactic body radiotherapy (SBRT) versus surgery for the treatment of early stage non-small cell lung cancer: a systematic review and meta-analysis. Radiother. Oncol. 112(2), 250\u2013255 (2014).","journal-title":"Radiother Oncol."},{"key":"73177_CR28","doi-asserted-by":"publisher","first-page":"100298","DOI":"10.1016\/j.ctarc.2020.100298","volume":"26","author":"S Azghadi","year":"2021","unstructured":"Azghadi, S. & Daly, M. E. Radiation and immunotherapy combinations in non-small cell lung cancer. Cancer Treat. Res. Commun. 26, 100298 (2021).","journal-title":"Cancer Treat. Res. Commun."},{"key":"73177_CR29","doi-asserted-by":"crossref","unstructured":"Chen, P. et al. Non-small cell lung cancer in China. Cancer Commun. (London), 42(10), 937\u2013970 (2022) .","DOI":"10.1002\/cac2.12359"},{"issue":"1","key":"73177_CR30","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-020-00940-z","volume":"13","author":"Y Chen","year":"2020","unstructured":"Chen, Y. et al. SBRT combined with PD-1\/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges. J. Hematol. Oncol. 13 (1), 105 (2020).","journal-title":"J. Hematol. Oncol."},{"issue":"8","key":"73177_CR31","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.it.2018.06.001","volume":"39","author":"ME Rodriguez-Ruiz","year":"2018","unstructured":"Rodriguez-Ruiz, M. E. et al. Immunological mechanisms responsible for radiation-induced abscopal effect. Trends Immunol. 39 (8), 644\u2013655 (2018).","journal-title":"Trends Immunol."},{"issue":"1","key":"73177_CR32","doi-asserted-by":"publisher","first-page":"4866","DOI":"10.1038\/s41598-017-04978-x","volume":"7","author":"T Zhang","year":"2017","unstructured":"Zhang, T. et al. Hypofractionated stereotactic radiation therapy activates the peripheral immune response in operable stage I non-small-cell lung cancer. Sci. Rep. 7 (1), 4866 (2017).","journal-title":"Sci. Rep."},{"key":"73177_CR33","doi-asserted-by":"crossref","unstructured":"Spaas, M. & Lievens, Y. Is the combination of immunotherapy and radiotherapy in non-small cell lung cancer a feasible and effective Approach?. Front. Med. (Lausanne), 6, 244 (2019).","DOI":"10.3389\/fmed.2019.00244"},{"key":"73177_CR34","doi-asserted-by":"publisher","first-page":"967360","DOI":"10.3389\/fonc.2022.967360","volume":"12","author":"H Yang","year":"2022","unstructured":"Yang, H. et al. A combined predictive model based on radiomics features and clinical factors for disease progression in early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy. Front. Oncol. 12, 967360 (2022).","journal-title":"Front. Oncol."},{"issue":"2","key":"73177_CR35","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.radonc.2011.09.017","volume":"101","author":"NE Verstegen","year":"2011","unstructured":"Verstegen, N. E. et al. Outcomes of stereotactic ablative radiotherapy following a clinical diagnosis of stage I NSCLC: comparison with a contemporaneous cohort with pathologically proven disease. Radiother .Oncol. 101 (2), 250\u2013254 (2011).","journal-title":"Radiother Oncol."},{"key":"73177_CR36","doi-asserted-by":"crossref","unstructured":"Schneider, B. J. et al. Stereotactic body radiotherapy for early-stage non-small-cell lung cancer: American society of clinical oncology endorsement of the American society for radiation oncology evidence-based guideline. J. Clin. Oncol. 36(7), 710\u2013719 (2018).","DOI":"10.1200\/JCO.2017.74.9671"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-73177-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-73177-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-73177-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T12:08:18Z","timestamp":1733227698000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-73177-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,3]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["73177"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-73177-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,3]]},"assertion":[{"value":"10 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study has been approved by the Ethics Committee of Zhejiang Cancer Hospital (IRB-2023-588) with the informed consent of all participants and\/or their legal guardians.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"30076"}}